Abstracts tagged "mixed connective tissue disease (MCTD) and ribonucleoprotein (RNP)"

Abstract Number: 1265 • 2017 ACR/ARHP Annual Meeting
Impaired Cardiac Function in Juvenile Mixed Connective Tissue Disease Compared with Controls
Birgit Nomeland Witczak¹, Siri Opsahl Hetlevik², Zoltan Barth^1,3, Thomas Schwartz^4,5, Berit Flatø^2,6, Vibke Lilleby^2,6 and Ivar Sjaastad^1,6,7, ¹Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ²Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, ³Department of Pathophysiology and Gerontology, Medical School, University of Pècs, Pècs, Hungary, Pècs, Hungary, ⁴Oslo University Hospital and University of Oslo, Institute for Experimental Medical Research, Oslo, Norway, ⁵Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁶Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, ⁷Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway
Background/Purpose: Juvenile MCTD (JMCTD) is a heterogenic autoimmune disease, with SLE-, SSc- and PM/DM and RA like manifestations. Cardiac involvement is known in juvenile SLE,…
Abstract Number: 2849 • 2016 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients with Antibodies Against U1-Ribonucleoprotein Exhibit a Specific Pattern of Disease Manifestations
David Fernandez¹, Mikhail Olferiev¹, Leila Khalili¹, Kyriakos A. Kirou² and Mary K. Crow¹, ¹Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies against nucleic acids and a variety of self-antigens. Recent work…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].